Abstract: OBJECTIVE To investigate the clinical response and adverse effects of combination chemotherapy based on pegylated liposomal doxorubicin(PLD) in advanced cancers treatment. METHODS A retrospective analysis was carried out in advanced cancer patients combined chemotherapy with pegylated liposomal doxorubicin from Jan, 2007 to Nov, 2009, and these patients were followed up till April 30, 2010. And the effiecy and safty of PLD were evaluated. RESULTS Thirty three patients had received 106 cycles of chemotherapy, 3 median cycles (range 1-8). Of the twenty-eight patients evaluated, 4 patients achieved complete response (14.3%), 11 patients partial response (39.3%), 11 patients stable disease (39.3%), and 2 patients progressive disease (7.1%). The objective response rate was 53.6% and the clinical benefit rate was 92.9%. The median follow-up time for the patients was 16 months (ranging from 6 to 39 months). Survival time interval of these patients were from 4 to 39 months, the median survival time was 16 months, progression-free survival 2-39 months, the median progression-free survival 10 months, the one- and the two-year survival rate was 69.2% and 34.2%, respectively, 3 cases of patients survived more than 3 years. The major adverse effects were myelosuppression, alopecia and gastrointestinal reaction. Asthenia and hand-foot syndrome were observed. Cardiac toxicity seldom occurred. CONCLUSION The combination chemotherapy based on pegylated liposomal doxorubicin in advanced cancers is efficient and well tolerated.